Project description DEENESFRITPL Utilising the wisdom of a plant to treat sexual dysfunction Sexual dysfunction has a serious negative effect on quality of life as well as socioeconomic impacts. The current treatments fail to offer a more natural sex life that does not involve prior planning as a prerequisite for sexual intercourse. A novel drug candidate for the treatment of the common types of sexual dysfunction is DIC2024. DIC2024 utilises a principle from Libiguin, a substance derived from a native plant in Madagascar, to induce long-term effects. The EU-funded LIBSED project is developing a business plan to guide clinical development and commercialisation strategies for DIC2024. Show the project objective Hide the project objective Objective This project will develop a business plan to guide clinical development and commercialization strategies for DIC2024, a novel drug candidate for the treatment of the common types of sexual dysfunction (SD): erectile dysfunction (ED) and premature ejaculation (PE) that affects 2 billion men worldwide. SD has serious implications on quality of life and is a significant socioeconomic burden. Current standard-of-care includes the use of PDE-5 inhibitors for ED and limited options for PE. The available treatments do not give long effect duration and therefore a major criticism is their inability to facilitate a more natural sex life that does not require planning every time a couple wants to have sexual intercourse. This is also related to delayed efficacy (15-60 mins) when using PDE-5 inhibitors.Accordingly, Dicot has developed DIC2024 that utilises a principle from a plant called Libiguin. Libiguin exerts a slow-onset, long-term action on the CNS’s integrative control systems for sexual behavior, which in turn controls spinal neuronal efferents that control erection and sexual behaviour. It also includes integration of afferent stimuli (tactile, visual, auditory). DIC2024’s uniqueness therefore lies in its potential to induce long term effects to tackle SD. The preclinical work performed to date includes development of the production protocol and studies to characterize the compound. Coupled with ethnopharmacological data (traditional medicine practiced by ethnic groups) supporting clinical use of Libiguin in men with SD, there is significant promise for the use of DIC2024 in the treatment of ED and PE. The proposed project will further prepare DIC2024 for a first-in-human clinical trial. SME Instrument funding will allow Dicot to take substantial steps along the path of commercialisation. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoveryengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringcontrol systemsmedical and health sciencesclinical medicineintegrative and complementary medicinemedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator DICOT AB Net EU contribution € 50 000,00 Address Dag hammarskjolds vag 30 752 37 Uppsala Sweden See on map Region Östra Sverige Östra Mellansverige Uppsala län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
